YTHDF2 Orchestrates Tumor-Associated Macrophage Reprogramming and Controls Antitumor Immunity through CD8⁺ T Cells

Selectively targeting YTHDF2 in tumor-associated macrophages (TAMs) using a Toll-like receptor 9 agonist-conjugated small interfering RNA reprogrammed TAMs toward an antitumoral phenotype, restrained tumor growth, and enhanced the efficacy of PD-L1 antibody therapy.